Introduction
Nasopharyngeal cancer (NPC) is highly prevalent in Asian populations, while it is rare among Caucasians [17, 44] . Historically, the local control for early stage reaches 80-90%, whereas T3-T4 tumors have a control rate of 30-65% [14, 25, 32] . Improvement in technical accuracy and radiotherapy delivery has been linked with improved tumor control [36] .
Various methods have been used to improve local control by increasing the dose delivered, including brachytherapy [6, 37] , stereotactic radiotherapy [13] , three-dimensional conformal radiotherapy [39, 42] and intensity-modulated radiotherapy (IMRT) [3, 22, 40] . IMRT allows for the simultaneous delivery of different doses to different target volumes, representing an ideal technique for localized dose escalation [26, 31] .
WHO (World Health Organization) histology type is regarded as an independent prognostic factor for survival in NPC, with less favorable prognosis in squamous WHO type 1 [5, 29] . Also, patients of Asian origin are considered to have improved survival when compared to non-Asians [2, 24] . Dose-volume histogram (DVH) comparison between institutions remains difficult, as there does not yet exist an international standardization regarding contouring definition, prescription dose, volume-related dose distribution and IMRT fractionation and dose normalization.
We evaluate the outcome and toxicity profile of chemo-SIB-(simultaneous integrated boost-)IMRT in our predominantly Caucasian collective characterized by a high proportion of unfavorable WHO type 1 histology. Results were analyzed with respect to the DVH values resulting from our SIB-IMRT dose definition.
Patients and Methods

Patient, Disease and Staging Characteristics
Between March 2002 and January 2008, 39 patients underwent IMRT for NPC at our department. All were staged using the 2002 American Joint Committee on Cancer (AJCC) criteria [9] .
Pretreatment evaluation included complete history, physical examination, direct flexible fiberoptic endoscopy, magnetic resonance imaging (MRI) scans of the nasopharynx, skull base and neck, chest computed tomography (CT) or X-ray, laboratory studies, and dental evaluation. Most patients (> 90%) underwent fused CT-positron emission tomography (PET) initially.
Patient and disease characteristics are listed in Table 1 . Mean age of the cohort was 53 years (16-78 years) . TN staging is outlined in Table 2 .
IMRT Planning
Patients were immobilized from head to shoulders with commercially available thermoplastic masks and an individually N0  N1  N2  N3  Total  T1  1  0  4  0  5  T2  1  4  6  1  12  T3  0  1  2  1  4  T4  4  5  9  0  18   Total  6  10  21  2  39 customized bite block. CT images (2 mm slice thickness) were acquired from the top of vertex to the level of the carina. The target volumes were drawn on each axial planning CT slice, based on diagnostic CT images, supplemented with fused diagnostic MRI and/or PET-CT scans. The gross tumor volume (GTV) included the gross extent of the primary disease and involved lymph nodes. PTV1 (planning target volume) was defined by adding a 0-to 15-mm margin to GTV, dependent on the GTV proximity to critical structures. PTV2 covered areas at high risk for potential microscopic disease. PTV3 included the clinically negative bilateral cervical lymphatics down to the supraclavicular fossae (elective PTV).
Organs at risk were outlined in three dimensions with an estimated planning organ-at-risk volume (PRV) margin of 2-10 mm.
We used an extended-field IMRT (EF-IMRT) technique, where the primary was treated in one phase along with the regional lymph nodes. Irradiation was delivered with five or seven coplanar beam angles by a 6-MV dynamic multileaf collimator (MLC) system (sliding-window technique; Varian Medical Systems, Palo Alto, CA, USA). Example of a five-field inverse plan is shown in Figure 1 .
Prescription Dose
As previously described [33] , SIB-IMRT was performed using the following schedules (five fractions/week each):
• SIB2.00: daily dose 2.00 Gy (PTV1)/1.70 Gy (PTV2)/1.54 Gy (PTV3); total dose: 70.00 Gy (n = 17); • SIB2.11: daily dose 2.11 Gy (PTV1)/1.80 Gy (PTV2)/1.64 Gy (PTV3); total dose: 69.60 Gy (n = 19); • SIB2.20: daily dose 2.20 Gy (PTV1)/2.00 Gy (PTV2)/1.80 Gy (PTV3); total dose: 66.00 Gy (n = 3).
The mean total treatment time was 46.7 days (33-58 days).
In cases with central nervous system involvement, the D max accepted was 2.00 Gy (SIB2.00). The dose was normalized to the mean dose in PTV1. For intensity optimization the prescribed dose should encompass at least 95% of the PTV. No more than 20% of any PTV would receive > 110% of its prescribed dose, while no more than 1% of any PTV would receive < 93% of the desired dose. (77%) completed five to seven concurrent cycles. In patients in whom cisplatin was contraindicated, carboplatin was substituted (n = 3).
Chemotherapy
Follow-Up
Institutional standards for posttreatment patient assessment included physical examination with additional fiberoptic nasopharyncoscopy at the Department of Head and Neck Surgery approximately every 2 months in the 1st year of follow-up, every 3 months in the 2nd year, every 6 months in the 3rd-5th year, and annually thereafter. A baseline MRI scan of the nasopharynx and neck was obtained within 3-6 months. Suspected findings were specified with PET-CT and were histologically proven.
Normal-tissue effects were graded according to the Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) radiation morbidity scoring criteria [10] . Xerostomia was subjectively assessed by the patients.
Statistical Analysis
Statistical calculations were performed using StatView ® program (Abacus Concepts Inc., CA). p-values of ≤ 0.05 were considered statistically significant.
Results
Treatment Outcome and Patterns of Failure
Analysis was based on follow-up data available as of January 1, 2009. The median follow-up was 30 months (range: 8-71 months).
The actuarial 3-year local relapse-free, nodal relapse-free, distant metastases-free and disease-free rates were 86%, 89%, 85%, and 72%, respectively ( Figure 2 ). The 3-year estimate of overall survival was 85%. At the time of analysis, 29 patients were alive with no evidence of disease (75%), four were alive with local and/or distant disease (10%), four died of disease (10%), and two died with intercurrent disease (5%; Table 3 ).
Prognostic Factors
Univariate analysis was performed to examine the impact of various prognostic factors. Differences in overall survival according to histology were statistically significant with worst prognosis in WHO type 1 [38] compared to WHO type 2/3 (75% vs. 93%; p = 0.03). There was also a trend in favor of WHO type 2/3 regarding local control (74% vs. 94%; p = 0.052).
Differences in 3-year local control rate according to T-stage were statistically significant, favoring T1/T2 lesions compared to T3/T4 (94% vs. 82%; p < 0.001).
Late Toxicity
There was no grade 4 late toxicity observed. The most common late effect was xerostomia. At the 12-month postirradiation follow-up, xerostomia grade 3 was assessed in three patients (8%), while five patients (13%) experienced xerostomia grade 2. At 24 months, grade 2 xerostomia was observed in four patients (10%). Grade 3 xerostomia insisted in two patients (5%), by whom the D 50 values (dose delivered to 50% of the organ volume) to the right/left parotid was 40.6 Gy/49.8 Gy and 35.2 Gy/48.0 Gy, respectively. T2 N2 M0  T4 N1 M0  T1 N2 M0  T3 N2 M1  T4 N0 M0  T4 N2 M0  T1 N2 M0  T2 N1 M0  Stage grouping  III  IVA  III  IVC  IVA  IVA  III  IIB  WHO histology  Type 1  Type 1  Type 1  Type 3  Type 1  Type 1  Type 3  Type 1  Grading (G)  G3  G3  G3  G3  G3  G3  G2  G2  EBV One patient developed cisplatin-related (five cycles concurrently) grade 3 hearing loss. The D 50 /D max values to the right and left middle/inner ear of the patient were 38.1 Gy/56 Gy and 34.0 Gy/55 Gy, respectively. One patient with T4 N1 disease developed dysphagia grade 3, which still persisted at 24-month follow-up, when he also remained PEG-(percutaneous endoscopic gastrostomy-)dependent; in this case, the caudal border of PTV1 was at the level of the glottic larynx. One patient presented with positive Lhermitte's sign at the 12-month clinical evaluation that resolved 4 months later. The D 5 (dose delivered to 5% of the organ volume)/D 10 (dose delivered to 10% of the organ volume) to the myelon PRV (myelon + 5-to 8-mm margin) were 42.7/39.6 Gy, respectively, while D mean /D max were 58.1/34.5 Gy.
In summary, persistent grade 3 late effects were observed in three patients (8%). There were no cases of temporal lobe necrosis, clinical optic neuropathy, osteoradionecrosis, severe soft-tissue fibrosis, or clinical hypopituitarism. Tables 4 and 5 show the DVH statistics for the target volumes. The maximum and minimum doses are point doses. Compared to the corresponding values published by others (Table 4) [22, 28] ), our GTV mean dose revealed to be ~ 3 Gy lower, while comparable nominal prescription dose was provided. The percentage of the GTV that received ≤ 95% of the prescribed dose remained equal. On the contrary, by the other series, the majority of the GTV received > 105% of the prescribed dose. This could raise a risk for lower tumor control in our cohort. However, there is no clear evidence for a loss of tumor control so far. Additionally, regarding optimal effective dose, there is a controversy in the optimal radiation dose, as, for example, in pediatric NPC, presenting mainly with WHO type 3 histology, it has been shown that radiation doses > 60 Gy appear necessary to achieve a high rate of locoregional control [41] . Table 6 shows the DVH statistics for the critical normal structures organized in series, while Table 7 outlines the DVH statistics for the normal tissues organized in parallel. Quantitative DVH analysis showed that there was significant sparing of the critical structures, a result that was consistent with the clinical observation of excellent treatment tolerance. DVH comparison of the normal structures organized in parallel showed lower dose values compared to that of Lee et al. [22] , which may in part explain the low rate of important late effects in our own series.
Dose-Volume Analysis
Discussion
Disease Control
IMRT series with altered fractionation schemes report local control rates of 84-98% and overall survival rates of 74-92%. However, the local failure rate remains still > 10% in patients with T3/T4 tumors [7, 15, 16, 18, 22, 27, 40, 43] .
In our study, the locoregional failure as well as diseasefree survival and overall survival rates are in the range of NPC IMRT series published so far (Table 8) , despite the fact that our cohort includes predominantly patients of Caucasian origin (95%), with a consecutively higher percentage of patients with WHO type 1 histology (41%) and a relatively greater proportion of patients with stage IV disease (54%), except for the study by Kwong et al. (72%) [20] . Postfailure analysis of isodose plans showed that all local recurrences were located within the high-dose volume, suggesting that contoured PTVs and the immobilization system were adequate. The absence of local failure in cases with GTV volume < 16 cm 3 may suggest adequate dose for small tumors [34] . A more effective dose may be required for locally advanced disease. Considering the favorable tolerance profile in our cohort, a careful dose increase may be possible (besides of other theoretical ways to biologically increase effectivity [19, 23] ).
All six patients with N0 status remained nodally controlled. As previously described [35] , in spite of our rather restrictive elective PTV definition regarding level I, none of the nodal recurrences were located in level I. One has, however, to consider that there was effective dose in level Ib, even in cases where this level was not included in PTV (Table 9) .
Evaluation of DVH analysis showed that our GTV DVH curves are slightly left-shifted compared to reported series [22, 27] (Table 4) . Lee et al. [22] explained the tumor overdosage by the fact that the prescribed dose was the minimum dose that encompassed the tumor target volume. Our left shift raises a risk for lower tumor control. However, there is no clear evidence for a loss of tumor control so far.
Comparisons of high-dose PTV DVH values [27, 28] are difficult and of limited meaning, as there are no international standards of IMRT schedules and the nominal doses are delivered using different dose constraints with different dose calculations to different related PTV definitions between centers. Toxicity IMRT-chemotherapy was well tolerated (no grade 4 late complications). In comparison to Lee et al. [22] , improved sparing of normal structures (parotid, temporomandibular joint, ear) in our study may in part explain the low rate of important late effects. As it has been estimated that parotid tolerance is likely a stepwise function [11] , our results could suggest that achievement of dose reduction at any dose level may improve the probability of parotid function. The compliance rate to chemotherapy was similar to other IMRT studies [4, 8, 12, 20, 22, 40] , as 69% of our patients completed the chemotherapy regimen protocol. In the Intergroup trial [1] , this number reached the proportion of only 55% in the adjuvant part, with the most frequently mentioned reason for noncompliance the refusal by the patient to undergo additional treatment and/or toxicity. A high level of compliance to chemotherapy seems important, as it has been suggested the addition of chemotherapy confers more benefit for WHO type 1 tumors than for type 3 tumors [30] .
Conclusion
The somewhat lower dose delivered to the high-dose PTV in our non-Asian NPC patients, presenting with less radioresponsive WHO type 1 histology and predominantly advanced stage, did not translate into a clearly lower disease control, while likely related to the very satisfactory treatment tolerance. As a consequence of the somewhat lower DVH values resulting from our IMRT dose specification, we changed the standardization of our internal IMRT dose constraints toward some higher GTV dosage by normalizing to the GTV (100% prescription of the isodose should surround GTV + 0-5 mm, resulting in a mean PTV GTV of ~ 103%), while the 95% isodoses should still surround the other PTVs. 
